Argus Research analyst John Staszak downgrades McCormick & Co (NYSE:MKC) from Buy to Hold.
Why Is Penny Stock Biophytis Trading Higher On Tuesday?
Announcing OBA clinical development program by Biophytis with BIO101 (20-hydroxyecdysone) for obesity treatment. Phase 2 study expected mid-2024, with efficacy results anticipated in 2025.